2025 Latin America 23-Valent Pneumococcal Vaccine Market Revenue Opportunities Report
Description
The 2025 Latin America 23-Valent Pneumococcal Vaccine Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the 23-valent Pneumococcal Vaccine Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the 23-valent pneumococcal vaccine market in Latin America are Pfizer Inc., Merck & Co., Inc., Sinovac, and the Serum Institute of India Pvt. Ltd. Pfizer leads with local production of its Prevnar 20 vaccine through a collaboration with Argentina’s Sinergium Biotech and support from PAHO, ensuring increased regional access and competitive pricing starting in 2025–2026. Merck holds the largest global market share of about 78% for 23-valent pneumococcal polysaccharide vaccines and is a key supplier in the region alongside Sinovac and Serum Institute of India Pvt. Ltd., both of which have significant footprints in Latin America (PAHO, FiercePharma, Valuates, Datamintelligence).
Pfizer’s extensive engagement includes technology transfer for local vaccine production in Argentina, bolstering availability across Latin America via PAHO’s Revolving Fund, which facilitates joint vaccine purchases by countries in the region. Merck and Sinovac are recognized for their polysaccharide vaccine variants, with Merck dominating globally, while Serum Institute of India Pvt. Ltd. supports broad regional demand. These companies collectively drive market growth supported by government immunization programs and increasing pneumonia prevalence. The Latin American pneumococcal vaccine market is expected to grow at a CAGR of about 16% from 2024 to 2030, emphasizing the growing role of these major players (PAHO, FiercePharma, Grandview Research, Datainsights).
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the 23-valent Pneumococcal Vaccine Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the 23-valent pneumococcal vaccine market in Latin America are Pfizer Inc., Merck & Co., Inc., Sinovac, and the Serum Institute of India Pvt. Ltd. Pfizer leads with local production of its Prevnar 20 vaccine through a collaboration with Argentina’s Sinergium Biotech and support from PAHO, ensuring increased regional access and competitive pricing starting in 2025–2026. Merck holds the largest global market share of about 78% for 23-valent pneumococcal polysaccharide vaccines and is a key supplier in the region alongside Sinovac and Serum Institute of India Pvt. Ltd., both of which have significant footprints in Latin America (PAHO, FiercePharma, Valuates, Datamintelligence).
Pfizer’s extensive engagement includes technology transfer for local vaccine production in Argentina, bolstering availability across Latin America via PAHO’s Revolving Fund, which facilitates joint vaccine purchases by countries in the region. Merck and Sinovac are recognized for their polysaccharide vaccine variants, with Merck dominating globally, while Serum Institute of India Pvt. Ltd. supports broad regional demand. These companies collectively drive market growth supported by government immunization programs and increasing pneumonia prevalence. The Latin American pneumococcal vaccine market is expected to grow at a CAGR of about 16% from 2024 to 2030, emphasizing the growing role of these major players (PAHO, FiercePharma, Grandview Research, Datainsights).
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
